25 valent pneumococcal conjugate vaccine
Vaccineexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 28, 2022 (NCT05540028)
Timeline
Indications
Studied for
Mechanism of action
- Streptococcus pneumoniaeImmunity, active
Streptococcus pneumoniae immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06077656 | Phase 2 | Oct 25, 2023 | Canadian Center for Vaccinology, Inventprise Inc., PATH, University of British Columbia |
| NCT05540028 | Phase 1/Phase 2 (Phase 2) | Sep 28, 2022 | Canadian Center for Vaccinology, Inventprise Inc., PATH, University of British Columbia |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Canadian Center for Vaccinology | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Inventprise Inc. | For profit | 2 | 2 | 1 | 2022 |
| PATH | Academic/Hospital | 2 | 0 | 1 | 2022 |
| University of British Columbia | Academic/Hospital | 2 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1